Open AccessAre the Newer Antidiabetic Agents Worth the Cost?
Author(s) -
Sudhakar Pemminati,
Richard M. Millis,
Ashwin Kamath,
Ashok K Shenoy,
Shivapraksh Gangachannaiah
Publication year - 2016
Publication title -
journal of clinical and diagnostic research
Language(s) - English
Resource type - Journals
eISSN - 2249-782X
pISSN - 0973-709X
DOI - 10.7860/jcdr/2016/17683.7384
Subject(s) - medicine , exenatide , glimepiride , liraglutide , sitagliptin , metformin , type 2 diabetes mellitus , canagliflozin , saxagliptin , pioglitazone , pharmacology , dapagliflozin , linagliptin , intensive care medicine , diabetes mellitus , type 2 diabetes , endocrinology